FIELD: medicine. SUBSTANCE: method involves examining vulva cancer patients belonging to III clinical group in dynamic mode after applying antitumor treatment. Daily melatonin excretion is determined in urine. Marked daily melatonin level increase, 2-3 times as large when compared to a reference value, being observed, vulva cancer recurrence is predicted to take place in 2-4 months. EFFECT: enhanced reliability of prognosis.
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING GENERALIZATION OF MAMMARY CANCER | 2001 |
|
RU2204836C2 |
METHOD FOR PREDICTING THE DURATION OF RELAPSE-FREE PERIOD IN PATIENTS WITH MAMMARY CANCER | 2003 |
|
RU2251692C2 |
METHOD FOR PREDICTING RELAPSE OF MAMMARY CANCER | 2003 |
|
RU2263319C2 |
METHOD FOR PREDICTION OF RECURRENT VULVAR CANCER | 2013 |
|
RU2517541C1 |
METHOD FOR PREDICTING METASTASIS AND FLOW OF TUMOR PROCESS IN PATIENTS WITH PULMONARY CANCER | 2002 |
|
RU2214605C1 |
METHOD FOR PREDICTION OF RECURRENT CARCINOMA OF VULVA | 2013 |
|
RU2532342C1 |
METHOD OF PREDICTION OF RECURRENT VULVAR CANCER I AND II STAGE | 2015 |
|
RU2608508C1 |
METHOD FOR PREDICTING RELAPSES IN SKIN MELANOMA PATIENTS | 2004 |
|
RU2275637C2 |
METHOD FOR PREDICTING INDIVIDUAL TUMOR SENSITIVITY TO CHEMOTHERAPY | 2000 |
|
RU2179725C2 |
METHOD FOR CORRECTING FUNCTIONAL MELATONIN PRODUCTION ACTIVITY OF EPIPHYSIS IN TREATING THE CASES OF LUNG CANCER | 2002 |
|
RU2241221C2 |
Authors
Dates
2000-07-20—Published
1998-06-30—Filed